Day: January 2, 2024

Petra WolfPetra Wolf, CMO at QuadientQuadient (Euronext Paris: QDT), a leader in helping businesses create meaningful customer connections through digital and physical channels, today announced the appointment of Petra Wolf as new Chief Marketing Officer, effective January 2, 2024. With a professional journey spanning more than 20 years, Petra Wolf has excelled in senior management positions within the spheres of B2B and B2C technology marketing. Her seasoned expertise extends across various tech-related industries, encompassing semi-conductors, server and client hardware, consulting, and software development. Prior to joining Quadient, Petra successfully steered Global Marketing for Small and Medium Businesses at Amazon Web Services, where she demonstrated her ability to identify and capitalize on market opportunities through...

CALGARY, Alberta, Jan. 02, 2024 (GLOBE NEWSWIRE) — DIVERGENT Energy Services Corp. (the “Corporation“) announces that it has closed its shares for interest transaction by electing to satisfy the interest obligation on its debentures (“Debentures“) in the amount of $36,232.88 due on December 31, 2023 (the “Interest Obligation“) by the issuance of 1,767,458 common shares of the Corporation (“Common Shares“) at a deemed price of $0.0205 per Common Share to the holders of Debentures. The transaction is subject to the final approval of the TSX Venture Exchange (“TSXV“) and is pursuant to the Corporation’s right to satisfy its interest obligation owed on the Debentures. The Common Shares issued pursuant to the Interest Obligation are subject to the minimum pricing rules...

SAN CARLOS, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — Check Point® Software Technologies Ltd. (NASDAQ: CHKP), a leading provider of cyber security solutions globally, today announced that it will release its financial results for the fourth quarter and full year 2023 ended December 31, 2023, on Tuesday, February 6, 2024, before the U.S. financial markets open. Management will host a video conference call with the investment community at 8:30 AM EDT/5:30 AM PST on February 6, 2024. A live video webcast of the call will be hosted on the company’s website at http://www.checkpoint.com/ir. To follow this and other Check Point news visit:Twitter: http://www.twitter.com/checkpointsw Facebook: http://www.facebook.com/checkpointsoftware Blog: http://blog.checkpoint.com/ YouTube: http://www.youtube.com/user/CPGlobal LinkedIn: https://www.linkedin.com/company/check-point-software-technologiesAbout...

NEW YORK, Jan. 02, 2024 (GLOBE NEWSWIRE) — Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Chairman, is scheduled to present at the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024 at 8:15 a.m. PT in San Francisco, CA. The live and archived webcast can be accessed under “Events & Presentations” in the Investor Relations section of the Company’s website at www.intracellulartherapies.com. Please log in approximately 5-10 minutes prior to the event to register and to download and install any necessary software. About Intra-Cellular Therapies Intra-Cellular Therapies is a biopharmaceutical...

   LYON, France, January 2, 2024 – EDAP TMS SA (Nasdaq: EDAP), (“EDAP”), the global leader in robotic energy-based therapies, today announced that the Company has appointed Ken Mobeck as its Chief Financial Officer of EDAP worldwide, and Francois Dietsch as Global Chief Accounting Officer. Both appointments are effective as of January 1, 2024. “Over the past year, we have continued to align our organization in support of our strategic growth initiatives to build shareholder value by focusing on expanding our operational and commercial presence in the U.S.,” said Ryan Rhodes, Chief Executive Officer of EDAP. “Based on Ken’s extensive experience in global finance, investor relations and operations, this appointment to Global Chief Financial Officer is consistent with our ongoing alignment and will enable EDAP to remain focused on executing...

NEWARK, Calif., Jan. 02, 2024 (GLOBE NEWSWIRE) — CymaBay Therapeutics, Inc. (NASDAQ: CBAY), a biopharmaceutical company focused on innovative therapies for patients with liver and other chronic diseases, today announced that its President and Chief Executive Officer, Sujal Shah, will present at the upcoming 42nd Annual JP Morgan Healthcare Conference taking place January 8 -11 in San Francisco, California.42nd Annual JP Morgan Healthcare ConferenceDate:     Wednesday, January 10, 2024Time:     4:30pm PT/ 7:30pm ETLocation:     Grand Ballroom, The Westin St. Francis Hotel, San FranciscoWebcast:     http://ir.cymabay.com/eventsAbout CymaBayCymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on improving the lives of people with liver and other chronic diseases that have high unmet medical...

Boca Raton, Florida, Jan. 02, 2024 (GLOBE NEWSWIRE) —  INmune Bio, Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company focused on developing treatments that harness the patient’s innate immune system to fight  disease, dosed the first patient in the Phase I/II trial in men with metastatic castration-resistant prostate cancer (mCRPC) on December 27, 2023. INKmune™ is a biologic therapy given as out-patient therapy without the need for pre-medication or cytokine support. “Results of immunotherapy trials for mCRPC have been disappointing,” said Professor Matt Rettig, Professor of Medicine and Urology, Medical Director of the Prostate Cancer Program at the David Geffen School of Medicine at UCLA and member of the Jonsson Comprehensive Cancer Center. “After many failures using T-cell focused immunotherapy...